Review of bosentan in the management of pulmonary arterial hypertension

Vascular Health and Risk Management

Volumn 3, Issue 6, 2007, Pages 887-900

  Gabbay, Eli ^a   Fraser, John ^b   McNeil, Keith ^b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

Bosentan; Pulmonary arterial hypertension; Review

Indexed keywords

ALANINE AMINOTRANSFERASE; AMBRISENTAN; AMINOTRANSFERASE; ANTIBIOTIC AGENT; ARGININE; ASPARTATE AMINOTRANSFERASE; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; HEMOGLOBIN; ILOPROST; INFLUENZA VACCINE; LIVER ENZYME; NITRIC OXIDE; ORAL CONTRACEPTIVE AGENT; PLACEBO; PNEUMOCOCCUS VACCINE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; SITAXSENTAN; TADALAFIL; TEPROSTINIL; UNCLASSIFIED DRUG; WARFARIN;

ADD ON THERAPY; ADJUVANT THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE PAIN; CARDIOPULMONARY HEMODYNAMICS; CHILD HEALTH CARE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGENITAL HEART DISEASE; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE DISEASE; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DISEASE CLASSIFICATION; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EISENMENGER COMPLEX; ENDARTERECTOMY; EVIDENCE BASED MEDICINE; EXERCISE TOLERANCE; FLUSHING; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENOTYPE ENVIRONMENT INTERACTION; HEALTH CARE ACCESS; HEART SURGERY; HEMATOCRIT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOXEMIA; JAW DISEASE; LONG TERM CARE; LOW DRUG DOSE; LUNG EMBOLISM; LUNG TRANSPLANTATION; METHEMOGLOBINEMIA; MONOTHERAPY; NONHUMAN; OPEN STUDY; OXYGEN THERAPY; PATHOGENESIS; PATIENT MONITORING; PULMONARY HYPERTENSION; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; REVIEW; SCLERODERMA; SIDE EFFECT; SURVIVAL RATE; SYNCOPE; THROMBOCYTE DYSFUNCTION; TREATMENT DURATION;

ANTIHYPERTENSIVE AGENTS; CONNECTIVE TISSUE DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENDOTHELIN-1; HUMANS; HYPERTENSION, PULMONARY; PEDIATRICS; QUALITY OF LIFE; SULFONAMIDES;

EID: 38149026958     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. ASTP, ATS, ERS, ISHLT joint statement. 1998. International guidelines for the selection of lung transplant patients. Am J Respir Crit Care Med, 158:335-9.
2. Barst RJ, Ivy D, Dingemanse J, et al. 2003. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther, 73:372-82.
3. Barst RJ, Rubin LJ, Long WA, et al. 1996. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med, 334:296-302.
4. Benedict NJ. 2007. Sitaxsentan in the management of pulmonary arterial hypertension. Am J Health-System Pharmacy, 64:363-8.
5. Benigni A, Ramuzzi G. 1999. Endothelin antagonists. Lancet, 353:133-8.
6. Black C. 2005. Pulmonary arterial hypertension: are we doing enough to identify systemic sclerosis patients at high risk of this rare condition? Rheumatology (Oxford), 44:141-2.
7. Bonderman D, Nowomy R, Skoro-Sajer N, et al. 2005. Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension. Chest, 128:2599-603.
8. Bresser P, Fedullo PF, Auger WR, et al. 2004. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J, D:595-600.
9. Channick RN, Simonneau G, Sitbon O, et al. 2001. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet, 358:1119-23.
10. Clozel M, Gray GA, Breu V, et al. 1992. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun, 186:867-73.
11. D'Alonzo GE, Barst RJ, Ayres SM, et al. 1991. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med, 115:343-9.
12. Denton CP, Humbert M, Rubin L, et al. 2006. Bosentan therapy for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis, 65:1336-40.
13. Doyle RL, McCrory D, Channick RN, et al. 2004. Journal of American College of Chest Physicians: Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest, 126(1S):63S-71S.
14. Farber HW, Loscalzo J. 2004. Pulmonary arterial hypertension. N Engl J Med, 351:1655-65.
15. Filep JG, Fournier A, Foldes-Filep E. 1995. Acute pro-inflammatory actions of endothelin-1 in the guinea pig lung: Involvement of ETA and ETB receptors. Br J Pharmacol, 115:227-36.
16. Fuster V, Steele PM, Edwards WD, et al. 1984. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation, 70:580-7.
17. Gabbay E, McNeil K, Williams TJ, et al. 2005. Bosentan for pulmonary arterial hypertension; the relationship between 6MWT and quality of life. Am J Resp Crit Care Med, 169:A175.
18. Gaine SP, Rubin LJ. 1998. Primary pulmonary hypertension. Lancet, 352:719-25.
19. Galic N. 2004. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J, 25:2243-78.
20. Galie N, Beghetti M, Gatzoulis MA, et al. 2006. Bosentan therapy in patients with Eisenmenger syndrome. Circulation, 114:48-54.
21. Galie N, Ghofrani HA, Torbicki A, et al. 2005. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med, 353:2148-57.
22. Galie N, Gjigioni F, Bacchi-Rggianin K, et al. 1996. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension. Eur J Clin Invest, 26:273.
23. Galie N, Hinderliter AL, Torbicki A, et al. 2003. Effects of the oral endothelin-receptor antagonist Bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol, 41:1380-6.
24. Galie N, Seeger W, Naeije R, et al. 2004. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol, 43:81S-88S.
25. Giaid A, Yanagisawa M, Langleben D, et al. 1993. Expression of Endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med, 328:1732-9.
26. Girgis RE, Mathai SC, Krishnan JA, et al. 2005. Long-Term outcome of Bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplantation, 24:1626-31.
27. Hoeper MM. 2002. Pulmonary hypertension in collagen vascular disease. Eur Respir J, 19:571-6.
28. Hoeper MM, Dinh-Xuan AT. 2004. Combination therapy for pulmonary arterial hypertension: still more questions than answers. Eur Respir J, 24:339-40.
29. Hoeper MM, Faulenbach C, Golpon H, et al. 2004. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J, 24:1007-10.
30. Hoeper MM, Kiely DG, Carlsen J, et al. 2005. Safety profile of pulmonary arterial hypertension patients treated with bosentan and sildenafil: results from the European surveillance program. Am J Resp Cnt Care Med, 169:A135.
31. Hoeper MM, Kramm T, Wilkens H, et al. 2005. Bosentan Therapy for Inoperable Chrome Thromboembolic Pulmonary Hypertension. Chest, 128:2363-7.
32. Hoeper MM, Markevych I, Spierkerkoetter E, et al. 2005. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J, 26:858-63.
33. Hughes R, George P, Parameshwar J, et al. 2005. Bosentan in inoperable chronic thromboembolic pulmonary hypertension. Thorax, 60:707.
34. Hughes RJ, Jais X, Bonderman D, et al. 2006. Bosentan in inoperable chronic thromboembolic pulmonary hypertension: efficacy at 1 year. Eur Respir J, 29:139-43.
35. Humbert M, Barst RJ, Robbins IM, et al. 2004. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J, 24:353-9.
36. Humbert M, Morrell NW, Archer SL, et al. 2004. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol, 43:13S-24S.
37. Humbert M, Sitbon O, Simonneau G. 2004. Treatment of pulmonary arterial hypertension. N Engl J Med, 351:1425-36.
38. Jais X, Ghofrani A, Hoeper MM, et al. 2007. Bosentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): a randomized, placebo-controlled trial. Am J Resp Crit Care Med, 173:A896.
39. Jamieson SW, Kapelanski DP, Sakakibara N, et al. 2003. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg, 76:1457-64.
40. Jones K, Higenbottam T, Wallwork J. 1989. Pulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertension. Chest, 96:784-9.
41. Katwa LC, Guarda E, Weber KT. 1993. Endothelin receptors in cultured adult rat cardiac fibroblasts. Cardiovasc Res, 27:2125-9.
42. Keogh AM, McNeil KD, Wlodarczyk J, et al. 2007. Quality of life in pulmonary arterial hypertension: improved and maintained with bosentan. J Heart Lung Transplantation, 26:181-7.
43. Kotlyar E, Sy R, Keogh AM. 2006. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease. Cardiol Young, 16:268-74.
44. Lane KB, Machado RD, Pauciulo MW, et al. 2000. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet, 26:91-4.
45. Levin ER. 1995. Endothelins. N Engl J Med, 333:356-63.
46. Lunze K, Gilbert N, Mebus S, et al. 2006. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. Eur J Clin Invest, 36S3:32-8.
47. McLaughlin VV, Oudiz RJ, Frost A, et al. 2006. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med, 174:1257-63.
48. McLaughlin VV, Sitbon O, Badesch DB, et al. 2005. Survival with firstline bosentan in patients with primary pulmonary hypertension. Eur Respir J, 25:244-9.
49. Moser KM, Auger WR, Fedullo PF. 1990. Chronic major-vessel thromboembolic pulmonary hypertension. Circulation, 81:1735-43.
50. Musk M, Chambers D, Lawrence S, et al. 2006. Bosentan improves WHO functional class, exercise capacity and RV size in inoperable chronic thromboembolic pulmonary hypertension (CTEPH). J Heart Lung Transplantation, 25:S77.
51. Newman JH, Wheller L, Lane KB, et al. 2001. Mutation in the gene for bone morphogenetic; protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med, 345:319-24.
52. Neylon CB, Avdonin PV, Dilley RJ, et al. 1994. Different electrical responses to vasoactive agonists in morphologically distinct smooth muscle cell types. Circ Res, 75:733-41.
53. Olschewski H, Simonneau G, Galie N, et al. 2002. Aerosolized Iloprost Randomized Study Group: Inhaled iloprost for severe pulmonary hypertension. N Engl J Med, 347:322-9.
54. Paul GA, Gibbs SR, Boobis AR, et al. 2005. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol, 60:107-12.
55. Provencher S, Sitbon O, Humbert M, et al. 2006. Long-term outcome with first line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J, 27:589-95.
56. Rich S, Kaufmann E, Levy PS, 1992. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med, 327:76-81.
57. Rosenzweig EB, Ivy DD, Wilditz A, et al. 2005. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol, 46:697-704.
58. Rubin LJ. 2004. ACCP evidence-based clinical practice guidelines: Diagnosis and management of pulmonary arterial hypertension. Chest, 126:1S-92S.
59. Rubin LJ, Badesch DB, Barst RJ, et al. 2002. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med, 346:896-903.
60. Rubin LJ, Hoeper MM, Klepetko W, et al. 2006. Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. Proc Am Thorac Soc, 3:601-7.
61. Runo JR, Loyd JE. 2003. Primary pulmonary hypertension. Lancet, 361:1533-44.
62. Simonneau G, Barst RJ, Galie N, et al. 2002. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med, 165:800-4.
63. Simonneau G, Galie N, Rubin LJ, et al. 2004. Clinical classification of pulmonary hypertension. J Am Coll Cardiol, 43:5S-12S.
64. Sitbon O, Badesch DB, Channick RN, et al. 2003. Effects of the dual endothelin receptor antagonist Bosentan in patients with pulmonary arterial hypertension: A 1-year follow-up study. Chest, 124:247-54.
65. Sitbon O, Gressin V, Speich R, et al. 2004. Bosentan in pulmonary arterial hypertension associated with HIV infection. Am J Respir Crit Care Med, 170:1212-17.
66. Sitbon O, Humbert M, Nunes H, et al. 2002. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol, 40:780-8.
67. Sitbon O, McLaughlin VV, Badesch DB, et al. 2005. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first-line oral bosentan compared with an historical cohort of patients started on iv epoprostenol. Thorax, 60:1025-30.
68. Steiner MK, Preston IR, Klinger JR, et al. 2006. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study. Chest, 130:1471-80.
69. Stewart S, Murphy NF, McMurray JJV, et al. 2007. A population-based analysis of pulmonary arterial hypertension in Scotland (1996-2001) Eur Respir J, (in press).
70. Strange C. 2005. Treatment for Secondary Pulmonary Hypertension. Chest, 128:1897-8.
71. Voelkel NF, Tuder RM, Weir EK. 1997. Pathophysiology of primary pulmonary hypertension: From physiology to molecular mechanisms. In: Rubin L, Rich S eds. Primary Pulmonary Hypertension, New York, NY: Marcel Deckerp 83-129.
72. Williams MH, Das C, Handler CE, et al. 2006. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart, 92:926-32.
73. Wlodarczyk JH, Cleland LG, Keogh AM, et al. 2006. Public funding of Bosentan for the treatment of pulmonary arterial hypertension in Australia. Pharmacoeconomics, 24:903-15.
74. Zapol WM, Falke KJ, Hurford WE, et al. 1994. Inhaling nitric oxide: a selective pulmonary vasodilator and bronchodilator. Chest, 105:87S-91S.